cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Denali Therapeutics Inc
11 own
5 watching
Current Price
$23.31
$0.27
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,761.56M
52-Week High
52-Week High
33.33000
52-Week Low
52-Week Low
14.56000
Average Volume
Average Volume
0.74M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
224.4045
iconMarket Capitalization3,761.56M
icon52-Week High33.33000
icon52-Week Low14.56000
iconAverage Volume0.74M
iconDividend Yield--
iconP/E Ratio224.4045
What does the Denali Therapeutics Inc do?
N/A
Read More
How much money does Denali Therapeutics Inc make?
News & Events about Denali Therapeutics Inc.
Zolmax
1 year ago
Denali Therapeutics Inc. (NASDAQ:DNLI Free Report) Director Vicki L. Sato sold 1,666 shares of the companys stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $29.84, for a total value of $49,713.44. Following the completion of the transaction, ...
Globe Newswire
1 year ago
Program uses Denalis Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.(Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) ...
Benzinga
1 year ago
Latest Ratings for DNLI DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Sep 2021OppenheimerInitiates Coverage OnOutperform Aug 2021Morgan StanleyMaintainsOverweight View More Analyst Ratings for DNLI View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution and ...
Zolmax
1 year ago
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Stock analysts at Wedbush increased their Q1 2023 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Tuesday, February 28th. Wedbush analyst L. Chico now expects that the company will earn ($0.69) per ...
Frequently Asked Questions
Frequently Asked Questions
What is Denali Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Denali Therapeutics Inc shares?
plus_minus_icon
How can I buy Denali Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Denali Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Denali Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Denali Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Denali Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Denali Therapeutics Inc?
plus_minus_icon
What percentage is Denali Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Denali Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.31
$0.27
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$62.03
$5.29 (9.33 %)
IMMATICS NV
IMMATICS NV
$5.44
$0.04 (0.74 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.16
$-0.03 (-1.37 %)
ImmunityBio Inc.
ImmunityBio Inc.
$3.21
$-0.01 (-0.16 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$62.03
$5.29 (9.33 %)
IMMATICS NV
IMMATICS NV
$5.44
$0.04 (0.74 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$2.16
$-0.03 (-1.37 %)
ImmunityBio Inc.
ImmunityBio Inc.
$3.21
$-0.01 (-0.16 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00